GAPDH binders as potential drugs for the therapy of polyglutamine diseases: Design of a new screening assay

FEBS Letters

Volumn 589, Issue 5, 2015, Pages 581-587

  Lazarev, Vladimir F ^a   Benken, Konstantin A ^b   Semenyuk, Pavel I ^c   Sarantseva, Svetlana V ^d   Bolshakova, Olga I ^d   Mikhaylova, Elena R ^a   Muronetz, Vladimir I ^c   Guzhova, Irina V ^a   Margulis, Boris A ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d KURCHATOV INSTITUTE   (Russian Federation)

Author keywords

Aggregation assay; dehydrogenase; Drug; Glyceraldehydes 3 phosphate; Polyglutamine diseases; Small molecule; Therapeutic target; Transgenic Drosophila; Transglutaminase

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYNONENAL; NEUROPROTECTIVE AGENT; PGL 135; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SELEGILINE; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; NEUROPROTECTION; NONHUMAN; POLYGLUTAMINE DISEASE; PROTEIN AGGREGATION; SCREENING TEST; ANIMAL; BIOASSAY; DISEASE MODEL; DROSOPHILA; HUNTINGTON DISEASE; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL ASSAY; DISEASE MODELS, ANIMAL; DROSOPHILA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUNTINGTON DISEASE; PEPTIDES;

EID: 84922714714     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.01.018     Document Type: Article

References (30)

1. C. Zuccato, M. Valenza, and E. Cattaneo Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol. Rev. 90 2010 905 981
2. B.A. Margulis, V. Vigont, V.F. Lazarev, E.V. Kaznacheyeva, and I.V. Guzhova Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors FEBS Lett. 587 2013 1997 2007
3. S. Kim, and K.T. Kim Therapeutic approaches for inhibition of protein aggregation in Huntington's disease Exp. Neurobiol. 23 2014 36 44
4. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 8 2012 143 149
5. J.L. Mazzola, and M.A. Sirover Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts Brain Res. Mol. Brain Res. 100 2002 95 101
6. M. Ruoppolo, S. Orrù, S. Francese, I. Caputo, and C. Esposito Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats Protein Sci. 12 2003 170 179
7. I.V. Guzhova, V.F. Lazarev, A.V. Kaznacheeva, M.V. Ippolitova, V.I. Muronetz, A.V. Kinev, and B.A. Margulis Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of Huntington disease Hum. Mol. Genet. 20 2011 3953 3963
8. I. Naletova, E. Schmalhausen, A. Kharitonov, A. Katrukha, L. Saso, A. Caprioli, and V. Muronetz Non-native glyceraldehyde-3-phosphate dehydrogenase can be an intrinsic component of amyloid structures Biochim. Biophys. Acta 1784 2008 2052 2058
9. K. Tsuchiya, H. Tajima, T. Kuwae, T. Takeshima, T. Nakano, M. Tanaka, K. Sunaga, Y. Fukuhara, K. Nakashima, E. Ohama, i.H. Mochizuk, Y. Mizuno, N. Katsube, and R. Ishitani Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions Eur. J. Neurosci. 21 2005 317 326
10. A. Pierce, H. Mirzaei, F. Muller, E. De Waal, A.B. Taylor, S. Leonard, H. Van Remmen, F. Regnier, A. Richardson, and A. Chaudhuri GAPDH is conformationally and functionally altered in association with oxidative stress in mouse models of amyotrophic lateral sclerosis J. Mol. Biol. 382 2008 1195 1210
11. V. Heiser, S. Engemann, W. Bröcker, I. Dunkel, A. Boeddrich, S. Waelter, E. Nordhoff, R. Lurz, N. Schugardt, S. Rautenberg, C. Herhaus, G. Barnickel, H. Böttcher, H. Lehrach, and E.E. Wanker Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Proc. Natl. Acad. Sci. U.S.A. 99 2002 16400 16406
12. J. Wang, S. Gines, M.E. MacDonald, and J.F. Gusella Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation BMC Neurosci. 6 2005
13. G.W. Carlile, R.M. Chalmers-Redman, N.A. Tatton, A. Pong, K.E. Borden, and W.G. Tatton Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer Mol. Pharmacol. 57 2000 2 12
14. W. Tatton, R. Chalmers-Redman, and N. Tatton Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B J. Neural. Transm. 110 2003 509 515
15. K. Uchida, and E.R. Stadtman Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction J. Biol. Chem. 268 1993 6388 6393
16. E. Hockly, J. Tse, A.L. Barker, D.L. Moolman, J.L. Beunard, A.P. Revington, K. Holt, S. Sunshine, H. Moffitt, K. Sathasivam, B. Woodman, E.E. Wanker, P.A. Lowden, and G.P. Bates Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease Neurobiol. Dis. 21 2006 228 236
17. N.W. Schiffer, S.A. Broadley, T. Hirschberger, P. Tavan, H.A. Kretzschmar, A. Giese, C. Haass, F.U. Hartl, and B.J. Schmid Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model Biol. Chem. 282 2007 9195 9203
18. K.A. Chernorizov, J.L. Elkina, P.I. Semenyuk, V.K. Svedas, and V.I. Muronetz Novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase: covalent modification of NAD-binding site by aromatic thiols Biochemistry (Moscow) 75 2010 1444 1449
19. R.K. Scopes, and A. Stoter Purification of all glycolytic enzymes from one muscle extract Methods Enzymol. 90 1982 479 490
20. B. Lomenick, R. Hao, N. Jonai, R.M. Chin, M. Aghajan, S. Warburton, J. Wang, R.P. Wu, F. Gomez, J.A. Loo, J.A. Wohlschlegel, T.M. Vondriska, J. Pelletier, H.R. Herschman, J. Clardy, C.F. Clarke, and J. Huang Target identification using drug affinity responsive target stability (DARTS) Proc. Natl. Acad. Sci. U.S.A. 106 2009 21984 21989
21. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
22. K.A. Markossian, H.A. Khanova, S.Y. Kleimenov, D.I. Levitsky, N.A. Chebotareva, R.A. Asryants, V.I. Muronetz, L. Saso, I.K. Yudin, and B.I. Kurganov Mechanism of thermal aggregation of rabbit muscle glyceraldehyde-3-phosphate dehydrogenase Biochemistry 45 2006 13375 13384
23. A. Colell, D.R. Green, and J.E. Ricci Novel roles for GAPDH in cell death and carcinogenesis Cell Death Differ. 16 2009 1573 1581
24. C. Tristan, N. Shahani, T.W. Sedlak, and A. Sawa The diverse functions of GAPDH: views from different subcellular compartments Cell. Signal. 23 2011 317 323
25. V.F. Lazarev, D.V. Sverchinskyi, M.V. Ippolitova, A.V. Stepanova, I.V. Guzhova, and B.A. Margulis Factors affecting aggregate formation in cell models of Huntington's disease and amyotrophic lateral sclerosis Acta Nat. 5 2013 81 89
26. P.R. Dahlgren, M.A. Karymov, J. Bankston, T. Holden, P. Thumfort, V.M. Ingram, and Y.L. Lyubchenko Atomic force microscopy analysis of the Huntington protein nanofibril formation Nanomedicine 1 2005 52 57
27. J. Legleiter, E. Mitchell, G.P. Lotz, E. Sapp, C. Ng, M. DiFiglia, L.M. Thompson, and P.J. Muchowski Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo J. Biol. Chem. 285 2010 14777 14790
28. T. Ishii, E. Tatsuda, S. Kumazawa, T. Nakayama, and K. Uchida Molecular basis of enzyme inactivation by an endogenous electrophile 4-hydroxy-2-nonenal: identification of modification sites in glyceraldehyde-3-phosphate dehydrogenase Biochemistry 42 2003 3474 3480
29. B. Lomenick, G. Jung, J.A. Wohlschlegel, and J. Huang Target identification using drug affinity responsive target stability (DARTS) Curr. Protoc. Chem. Biol. 3 2011 163 180
30. V. Heiser, E. Scherzinger, A. Boeddrich, E. Nordhoff, R. Lurz, N. Schugardt, H. Lehrach, and E.E. Wanker Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy Proc. Natl. Acad. Sci. U.S.A. 97 2000 6739 6744